{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:48:24Z","timestamp":1788922104896,"version":"build-2803163510"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"am","delay-in-days":204,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013116","name":"University Research Committee, Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["5UG3DA048775-02"],"award-info":[{"award-number":["5UG3DA048775-02"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.biomaterials.2024.122758","type":"journal-article","created":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T09:48:08Z","timestamp":1723974488000},"page":"122758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The immunological and pharmacokinetic evaluation of Lipid-PLGA hybrid nanoparticle-based oxycodone vaccines"],"prefix":"10.1016","volume":"313","author":[{"given":"Debra L.","family":"Walter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0585-3251","authenticated-orcid":false,"given":"Yuanzhi","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima A.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kobra","family":"Rostamizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Vigliaturo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4033-8017","authenticated-orcid":false,"given":"Riley","family":"DeHority","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Ehrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Runyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pravetoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6770-5334","authenticated-orcid":false,"given":"Chenming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biomaterials.2024.122758_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1215\/00703370-8937348","article-title":"The opioid epidemic and nonmarital childbearing in the United States, 2000-2016","volume":"58","author":"Caudillo","year":"2021","journal-title":"Demography"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122758_bib2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s12913-020-05390-4","article-title":"Clinical perspectives on hospitals' role in the opioid epidemic","volume":"20","author":"Mazurenko","year":"2020","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.biomaterials.2024.122758_bib3","series-title":"The American Opioid Epidemic in Special Populations: Five Examples","author":"Blanco","year":"2020"},{"issue":"8","key":"10.1016\/j.biomaterials.2024.122758_bib4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamapsychiatry.2018.0611","article-title":"Making the opioid public health emergency effective","volume":"75","author":"Haffajee","year":"2018","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.biomaterials.2024.122758_bib5","doi-asserted-by":"crossref","unstructured":"Dowell D, Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. . CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 71(3), 1\u201395. https:\/\/doi.org\/10.15585\/mmwr.rr7103a1.2022.","DOI":"10.15585\/mmwr.rr7103a1"},{"issue":"15","key":"10.1016\/j.biomaterials.2024.122758_bib6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.15585\/mmwr.mm7015a1","article-title":"State-level economic costs of opioid use disorder and fatal opioid overdose - United States, 2017","volume":"70","author":"Luo","year":"2021","journal-title":"MMWR. Morbidity and mortality weekly report"},{"key":"10.1016\/j.biomaterials.2024.122758_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume":"218","author":"Florence","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.biomaterials.2024.122758_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103555","article-title":"Trends in opioid-related crime incidents and comparison with opioid overdose outcomes in the United States","volume":"101","author":"Chen","year":"2022","journal-title":"Int. J. Drug Pol."},{"key":"10.1016\/j.biomaterials.2024.122758_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajem.2022.03.048","article-title":"Opioid usage and COVID-19 prognosis: a systematic review and meta-analysis","volume":"56","author":"Ao","year":"2022","journal-title":"Am. J. Emerg. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122758_bib10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11524-022-00610-0","article-title":"Impact of the COVID-19 pandemic on opioid overdose deaths: a spatiotemporal analysis","volume":"99","author":"Ghose","year":"2022","journal-title":"J. Urban Health"},{"key":"10.1016\/j.biomaterials.2024.122758_bib11","series-title":"The History of the Poppy and of Opium and Their Expansion in Antiquity in the Eastern Mediterranean Area","first-page":"17","author":"Kritikos","year":"1967"},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122758_bib12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.neuron.2011.02.001","article-title":"The doctor's dilemma: opiate analgesics and chronic pain","volume":"69","author":"Fields","year":"2011","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122758_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2049463712438493","article-title":"Basic opioid pharmacology: an update","volume":"6","author":"Pathan","year":"2012","journal-title":"Br. J. Pain"},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122758_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1522-8649(03)50051-8","article-title":"Scophedal (SEE) was it a fad or a miracle drug?","volume":"21","author":"Defalque","year":"2003","journal-title":"Bull. Anesth. Hist."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122758_bib15","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10571-020-01013-y","article-title":"Oxycodone in the opioid epidemic: high 'liking', 'wanting', and abuse liability","volume":"41","author":"Kibaly","year":"2021","journal-title":"Cell. Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122758_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12094-007-0057-9","article-title":"Oxycodone: a pharmacological and clinical review","volume":"9","author":"Ord\u00f3\u00f1ez","year":"2007","journal-title":"Clin. Transl. Oncol."},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122758_bib17","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"issue":"41","key":"10.1016\/j.biomaterials.2024.122758_bib18","doi-asserted-by":"crossref","first-page":"13879","DOI":"10.1523\/JNEUROSCI.2711-15.2015","article-title":"Pain and poppies: the good, the bad, and the ugly of opioid analgesics","volume":"35","author":"Trang","year":"2015","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122758_bib19","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.npp.1301471","article-title":"Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine","volume":"33","author":"Narita","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122758_bib20","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/npp.2008.134","article-title":"Behavioral and neurochemical changes induced by oxycodone differ between adolescent and adult mice","volume":"34","author":"Zhang","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biomaterials.2024.122758_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000324065","article-title":"Addiction and brain reward and antireward pathways","volume":"30","author":"Gardner","year":"2011","journal-title":"Adv. Psychosom. Med."},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122758_bib22","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","article-title":"The neuroscience of drug reward and addiction","volume":"99","author":"Volkow","year":"2019","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122758_bib23","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1152\/jn.00017.2021","article-title":"Neuronal mechanisms underlying opioid-induced respiratory depression: our current understanding","volume":"125","author":"Ramirez","year":"2021","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.biomaterials.2024.122758_bib24","series-title":"Bethesda (MD): National Library of Medicine (US)","year":"2004"},{"key":"10.1016\/j.biomaterials.2024.122758_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135177","article-title":"The antagonistic activity profile of naloxone in mu-opioid receptor agonist-induced psychological dependence","volume":"735","author":"Nakamura","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biomaterials.2024.122758_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.06.001","article-title":"Development of vaccines to treat opioid use disorders and reduce incidence of overdose","volume":"158","author":"Pravetoni","year":"2019","journal-title":"Neuropharmacology"},{"issue":"23","key":"10.1016\/j.biomaterials.2024.122758_bib27","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1016\/j.vaccine.2022.03.053","article-title":"Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder","volume":"40","author":"Hamid","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.biomaterials.2024.122758_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108653","article-title":"Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder","volume":"195","author":"Raleigh","year":"2021","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122758_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101807","article-title":"Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2024.122758_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1219985","article-title":"Development of a vaccine against the synthetic opioid U-47700","volume":"14","author":"Park","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.biomaterials.2024.122758_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184876","article-title":"Safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse","volume":"12","author":"Raleigh","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122758_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41541-021-00329-0","article-title":"Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge","volume":"6","author":"Stone","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122758_bib33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/pr.117.013904","article-title":"Conjugate vaccine immunotherapy for substance use disorder","volume":"69","author":"Bremer","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biomaterials.2024.122758_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.biomaterials.2017.01.038","article-title":"Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: a focus on hapten density","volume":"123","author":"Zhao","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2024.122758_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biomaterials.2017.05.031","article-title":"Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: a focus on hapten localization","volume":"138","author":"Zhao","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2024.122758_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.polymer.2015.10.048","article-title":"In vitro controlled release of antigen in dendritic cells using pH-sensitive liposome-polymeric hybrid nanoparticles","volume":"80","author":"Hu","year":"2015","journal-title":"Polymer (Guildf)"},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122758_bib37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.nano.2016.07.015","article-title":"A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy","volume":"13","author":"Zhao","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biomaterials.2024.122758_bib38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.biomaterials.2017.11.021","article-title":"Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction","volume":"155","author":"Zhao","year":"2018","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122758_bib39","article-title":"Chemical conjugation strategies for the development of protein-based subunit nanovaccines","volume":"9","author":"Lu","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122758_bib40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.111.189506","article-title":"An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia","volume":"341","author":"Pravetoni","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"31","key":"10.1016\/j.biomaterials.2024.122758_bib41","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1016\/j.vaccine.2012.04.101","article-title":"Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats","volume":"30","author":"Pravetoni","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122758_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1021\/bc5005262","article-title":"Long-term stabilization of maleimide-thiol conjugates","volume":"26","author":"Fontaine","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122758_bib43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4161\/hv.26635","article-title":"A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle","volume":"10","author":"Hu","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"23","key":"10.1016\/j.biomaterials.2024.122758_bib44","doi-asserted-by":"crossref","first-page":"14647","DOI":"10.1021\/acs.jmedchem.0c01042","article-title":"Therapeutic and prophylactic vaccines to counteract fentanyl use disorders and toxicity","volume":"63","author":"Robinson","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biomaterials.2024.122758_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13628-015-0023-9","article-title":"Copper-free click chemistry for attachment of biomolecules in magnetic tweezers","volume":"8","author":"Eeftens","year":"2015","journal-title":"BMC Biophys."},{"key":"10.1016\/j.biomaterials.2024.122758_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/srep21582","article-title":"Evaluation of the antinociceptive activities of enaminone compounds on the formalin and hot plate tests in mice","volume":"6","author":"Masocha","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122758_bib47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0160-5402(91)90014-V","article-title":"The increasing-temperature hot-plate test: an improved test of nociception in mice and rats","volume":"25","author":"Tjolsen","year":"1991","journal-title":"J. Pharmacol. Methods"},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122758_bib48","doi-asserted-by":"crossref","DOI":"10.1063\/1.4962992","article-title":"Physical characterization of nanoparticle size and surface modification using particle scattering diffusometry","volume":"10","author":"Clayton","year":"2016","journal-title":"Biomicrofluidics"},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122758_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S1369-7021(09)70164-6","article-title":"Light scattering and nanoparticles","volume":"12","author":"Nobbmann","year":"2009","journal-title":"Mater. Today"},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122758_bib50","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/andp.19083300302","article-title":"Beitr\u00e4ge zur Optik tr\u00fcber Medien, speziell kolloidaler Metall\u00f6sungen","volume":"330","author":"Mie","year":"1908","journal-title":"Ann. Phys."},{"issue":"Pt 4","key":"10.1016\/j.biomaterials.2024.122758_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1107\/S2053230X23002364","article-title":"Monomeric crystal structure of the vaccine carrier protein CRM(197) and implications for vaccine development","volume":"79","author":"Gallagher","year":"2023","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"key":"10.1016\/j.biomaterials.2024.122758_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/614383","article-title":"Humoral immune response to keyhole limpet haemocyanin, the protein carrier in cancer vaccines","volume":"2011","author":"Kantele","year":"2011","journal-title":"Clin. Dev. Immunol."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122758_bib53","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180238","article-title":"Structural and immunological characterization of E. coli derived recombinant CRM(197) protein used as carrier in conjugate vaccines","volume":"38","author":"Mishra","year":"2018","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122758_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/srep20488","article-title":"Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites","volume":"6","author":"M\u00f6ginger","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122758_bib55","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1124\/jpet.120.000014","article-title":"Combining a candidate vaccine for opioid use disorders with extended-release naltrexone increases protection against oxycodone-induced behavioral effects and toxicity","volume":"374","author":"Raleigh","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.biomaterials.2024.122758_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2019.102023","article-title":"Alum as an adjuvant for nanoparticle based vaccines: a case study with a hybrid nanoparticle-based nicotine vaccine","volume":"20","author":"Hu","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122758_bib57","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.nano.2018.04.016","article-title":"Hybrid nanoparticle-based nicotine nanovaccines: boosting the immunological efficacy by conjugation of potent carrier proteins","volume":"14","author":"Zhao","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biomaterials.2024.122758_bib58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s40064-015-0972-0","article-title":"The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm","volume":"4","author":"Ghimire","year":"2015","journal-title":"SpringerPlus"},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122758_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071884","article-title":"Aluminum Adjuvants-'Back to the future'","volume":"15","author":"Laera","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122758_bib60","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122758_bib61","doi-asserted-by":"crossref","first-page":"F103","DOI":"10.1152\/ajprenal.00064.2017","article-title":"Monophosphoryl lipid A induces protection against LPS in medullary thick ascending limb through a TLR4-TRIF-PI3K signaling pathway","volume":"313","author":"Watts","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"10.1016\/j.biomaterials.2024.122758_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/v11121118","article-title":"Monophosphoryl-lipid A (MPLA) is an efficacious adjuvant for inactivated rabies vaccines","volume":"11","author":"Chen","year":"2019","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122758_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/v15051198","article-title":"Efficiency of interferon-gamma in activating dendritic cells and its potential synergy with toll-like receptor agonists","volume":"15","author":"Bian","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.biomaterials.2024.122758_bib64","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3389\/fimmu.2020.01455","article-title":"Toll-like receptor 4 (TLR4)\/Opioid receptor pathway crosstalk and impact on opioid analgesia, immune function, and gastrointestinal motility","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122758_bib65","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/bph.12028","article-title":"Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4","volume":"168","author":"Stevens","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122758_bib66","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.4049\/jimmunol.1202658","article-title":"Morphine prevents lipopolysaccharide-induced TNF secretion in mast cells blocking IkappaB kinase activation and SNAP-23 phosphorylation: correlation with the formation of a beta-arrestin\/TRAF6 complex","volume":"191","author":"Madera-Salcedo","year":"2013","journal-title":"J. Immunol."},{"issue":"23","key":"10.1016\/j.biomaterials.2024.122758_bib67","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1073\/pnas.0402851101","article-title":"beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha","volume":"101","author":"Witherow","year":"2004","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1\u20132","key":"10.1016\/j.biomaterials.2024.122758_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-5728(96)00163-4","article-title":"Effect of morphine on lipopolysaccharide-induced tumor necrosis factor-alpha production in vivo: involvement of the sympathetic nervous system","volume":"73","author":"Bencsics","year":"1997","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.biomaterials.2024.122758_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2022.992087","article-title":"Characterization of KLH-driven immune responses in clinical studies: a systematic review","volume":"2","author":"Saghari","year":"2022","journal-title":"Frontiers in Drug Discovery"},{"issue":"30","key":"10.1016\/j.biomaterials.2024.122758_bib70","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1016\/j.vaccine.2020.05.027","article-title":"Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity","volume":"38","author":"Gradinati","year":"2020","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122758_bib71","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bcp.12422","article-title":"Keyhole limpet haemocyanin - a model antigen for human immunotoxicological studies","volume":"78","author":"Swaminathan","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.biomaterials.2024.122758_bib72","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-3024.1994.tb00306.x","article-title":"The profile of IgG1 and IgG2a antibody responses in mice exposed to Schistosoma mansoni","volume":"16","author":"Mountford","year":"1994","journal-title":"Parasite Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122758_bib73","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/ar383","article-title":"Th1 and Th2 cytokines regulate proteoglycan-specific autoantibody isotypes and arthritis","volume":"4","author":"Kaplan","year":"2002","journal-title":"Arthritis Res."},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122758_bib74","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1073\/pnas.94.4.1544","article-title":"Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia","volume":"94","author":"Sora","year":"1997","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.biomaterials.2024.122758_bib75","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8935085","article-title":"Evaluation of analgesic activity of papaver libanoticum extract in mice: involvement of opioids receptors","volume":"2017","author":"Hijazi","year":"2017","journal-title":"Evid Based Complement Alternat Med"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224002928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224002928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T20:00:53Z","timestamp":1726257653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961224002928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":75,"alternative-id":["S0142961224002928"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122758","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunological and pharmacokinetic evaluation of Lipid-PLGA hybrid nanoparticle-based oxycodone vaccines","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"122758"}}